The Food and Drug Administration approved new warnings for the diabetes drug Byetta Monday, adding cautions about links between Byetta and kidney problems.

Up to a third of children and adolescents who took common antipsychotic drugs for the first time became overweight or obese in as little as 11 weeks, raising their risk for diabetes and heart disease, U.S. researchers said on Tuesday.

A new study shows that a diabetes treatment awaiting FDA approval may also work as a weightloss drug.

Stocks finished lower after well-known banking analyst Dick Bove downgraded his rating on Wells Fargo.

Stocks advanced Wednesday as investors were encouraged by a few earnings reports, including Morgan Stanley, Yahoo and SanDisk. The VIX, widely considered the best gauge of fear in the market, dropped to just above 20.

Stocks opened lower Wednesday as a raft of companies beating earning estimates but failed to impress investors.

Eli Lilly posted better-than-expected quarterly profit on Wednesday as sales of its top-selling prescription drugs beat projections, and the drugmaker raised its full-year earnings forecast.

Earnings season continues in earnest Wednesday, as we roll on with a week that will ultimately see 25 percent of the S&P 500 report their quarterly numbers. 

What follows is a roundup of corporate earnings reports for Wednesday, Oct. 21.

Drugmaker Eli Lilly & Co says it will eliminate thousands of jobs and reorganize into five business units in an effort to slash costs and speed up development of potential new drugs.

Pfizer Inc. was slapped this week with a record $2.3 billion in fines for illegally marketing some drugs, but critics say even that eye-popping total is unlikely to end the practice.

Virtually every large pharmaceutical company seems to have discovered cancer, and a substantial portion of the smaller biotechnology companies are focused on it as well. Together, the companies are pouring billions of dollars into developing cancer drugs.

Use of antidepressant drugs in the United States doubled between 1996 and 2005, probably because of a mix of factors, researchers reported on Monday.

The Dow and S&P snapped their winning streaks Wednesday as disappointing earnings from two of Wall Street's biggest names overshadowed another round of earnings beats.

Stocks wobbled Wednesday as a slew of earnings beats, including one from Pfizer, were encouraging but disappointing reports from two of Wall Street's biggest names dragged on the market.